Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Pharmacokinetics in Chinese Crohn's Disease Patients
CTR20130986Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Adalimumab regimen A with Adalimumab regimen B + placebo (2 arms). Primary endpoint: Pharmacokinetics of two adalimumab dosing regimens. Started May 2014; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20130986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130986.